Martinez TJC, Seoane PJ, Li Pérez Y, Hernández VT, Aguirre AI, Morales JLC, Li PY

Language: Spanish
References: 11
Page:
PDF size: 267.34 Kb.

ABSTRACT

Guillain-Barré syndrome is an acute autoimmune polyradiculoneuropathy that affects peripheral nerves and nerve roots of the spinal cord. The incidence in the world is marked between 0,89-1,89 cases per 100 000 inhabitants / year with a male predominance of 1,78: 1. It has different forms of presentation, typical and atypical. It is clinically characterized by the presence of flaccid paralysis with dysflexia, variable sensory disorder and elevation of proteins in the cerebrospinal fluid. The diagnosis is clinical. It goes through 3 phases of evolution: progression, stabilization and regression. The estimated mortality is 4-8 %. More than 20 % of patients require assisted ventilation and 40 % of those who need hospitalization require rehabilitation; 80 % recover properly after treatment. The case is presented due to the atypical nature of its initial clinical picture with the taking of upper limbs and subsequently lower limbs, respiratory non-involvement and its favorable evolution with the rehabilitation treatment performed after the patient's clinical stabilization.

REFERENCES

1. Guía de práctica clínica. Diagnóstico y tratamiento del síndrome de Guillain-Barré en el segundo y tercer nivel de atención. Ciudad de México: Instituto Mexicano del Seguro Social; 2016.

2. Rebolledo-García D, González-Vargas PO, Salgado-Calderón I. Síndrome de Guillain-Barré: viejos y nuevos conceptos Med Int Méx. 2018 enero; 34(1):72-81.

3. Clifford R. History of British Neurology. 1a ed. Imperial College Press; 2012. Guillain Barré & Associated Inflammatory Neuropathies, 2010. (Accessed 7 February 2020, at http://www.gaincharity. org.uk/history-of-gbs/info_71.html).

4. REDALYC. OPS. Oficina regional para las Américas Boletín informativo sobre Guillain Barre. Síndrome de Guillain Barre. Actualización acerca del diagnóstico y tratamiento. Febrero 2016. http://www.redalyc.org/pdf/2111/211118126014.pdf

5. World Health Organization. Identification and management of Guillain-Barré syndrome in the context of Zika virus. URL: http: //www.who.int/csr/resources/publications/zika/ Guillain-barre-syndrome/en/. [08.02.2020].

6. Benavides-Melo JA, Rodríguez-Angulo GJ, Rosero Galindo CY, Montenegro-Coral FA, Lucero Coral NJ, Martínez-Villota VA, et al. Características Clínicas del Síndrome de Guillain-Barré en Relación a Chikungunya Y Zika: Revisión Sistemática. Revista Ecuatoriana de Neurología Vol. 27, No 2, 2018 pág.39-44.

7. Bonilla Pedroso NC, Terry Zamora A, Martínez Torres JC, García Delgado JA. Tratamiento fisiátrico en síndrome de Guillain-Barré postinfeccioso por virus Zika. PRESENTACIÓN DE CASO. Revista Cubana de Medicina Física y Rehabilitación 2018;10(3)

8. Revista Cubana de Medicina Militar, versión On-line ISSN 1561-3046, Rev Cub Med Mil v.8 n.2 Ciudad de la Habana abr.-jun. 2003, trabajos re revisión Instituto Superior de Medicina Militar “Dr. Luis Díaz Soto” http://scielo.sld.cu/scielo.php?pid=S0138-65572003000200009&script=sci_arttext

9. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain Barré syndrome. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-40.

10. Orange JS, Ochs HD, Cunningham-Rundles C. Prioritization of evidence-based indications for intravenous immunoglobulin. J Clin Immunol 2013; 33: 1033-6.

11. Del Carpio-Orantes L, Pola- Ramírez MR, García-Méndez S, Mata- Miranda MP, Perfecto-Arroyo MA, Solís-Sánchez I, et al. Agentes causales más frecuentes del síndrome de Guillain-Barré en un hospital general mexicano. Rev Neurol 2018; XX: XXX-XXX.